B Cell Receptors and Surface Markers
Native-like Structure. Bioactive Performance. Reliable Results.
Conigen’s recombinant B cell receptors (BCRs), including CD19 mimic native conformations and antigen responsiveness, supporting discovery in immunology, oncology, and antibody engineering.
The BCR complex enables antigen recognition and signaling in B cells, facilitating activation, differentiation, and memory formation. CD19 and CD27, Type I transmembrane proteins, are important markers on B cells involved in B cell function. CD19 is important for B cell development and acts as a co-receptor with the BCR to enhance signaling and activation. Dysregulation or overexpression of these molecules contributes to immune disorders and B-cell malignancies.
Conigen’s recombinant proteins enable the study of receptor clustering, epitope recognition, and therapeutic antibody interactions in native-like formats.
Available B Cell Receptors
| Protein | Tag | Product Code | Species | Homodimer/Heterodimer | Details | Quote |
|---|---|---|---|---|---|---|
| CD19 | His | CSP-24125-01 | Human | Homodimer | View Details | Request a Quote |
| CD19 | His | CSP-124-01 | Mouse | Homodimer | View Details | Request a Quote |
| CD19 | His | CSP-25291-01 | Rhesus Macaque | Homodimer | View Details | Request a Quote |
| CD19 | His-Avi | CSP-24125-03 | Human | Homodimer | View Details | Request a Quote |
Can’t Find the Protein You Need?
Spotlight: CD19
Bioactive Performance
CD19 is a coreceptor in the BCR complex and a central marker for B-cell targeting in immunotherapy. Although CD19 doesn’t form a dimer under physiological conditions, the CD19 overexpression and potential clustering in cancer cells enhance pro-survival signaling while posing challenges to immunotherapies. Targeting the overexpressed clustering CD19 may improve the therapeutic precision and overcome resistance.
Mouse CD19 protein dimer, His Tag (CSP-124-01) potently binds to CD19 specific monoclonal antibody (mAb) as measured by ELISA. The CD19 protein dimer (0.2 μg/ml) was coated on 96-well microtiter plates and detected by serial dilutions of anti-mouse CD19 mAb.
This recombinant protein supports structural and therapeutic research aimed at overcoming antigen escape and resistance in B-cell malignancies.